Huntexil Analysis Shows Slowed Decline in Total Functional Capacity

Huntexil Analysis Shows Slowed Decline in Total Functional Capacity

282634

Huntexil Analysis Shows Slowed Decline in Total Functional Capacity

Treatment with Huntexil (pridopidine) can slow the decline in total functional capacity in people with Huntington’s disease, a new analysis of clinical trial data indicate. The findings were published in the Journal of Huntington’s Disease, in two studies: “Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study” and “Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.” Huntexil is…

You must be logged in to read/download the full post.